The The Circulating Visfatin Level Relation to the Severity of Chronic Kidney Disease
DOI:
https://doi.org/10.3889/oamjms.2020.4582Keywords:
Chronic kidney disease, Adipokines, Visfatin, Estimated glomerular filtration rateAbstract
BACKGROUND: Adipokines have been associated with atherosclerotic heart disease, which has plenty of common risk factors with chronic kidney disease (CKD), but their association with CKD has not been well characterized.
AIM: We investigated the association between the serum visfatin level and CKD.
METHODS: The serum visfatin levels in 101 CKD patients and 101 controls were compared. CKD was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 or presence of albuminuria (≥30 mg/24 h).
RESULTS: After adjustment for established CKD risk factors, the median (interquartile range) of the serum visfatin was 3.65 ng/ml (2.31–4.59) in patients with CKD and 1.66 ng/ml (0.90–2.45) in controls without CKD (p < 0.0001 for group difference). Serum visfatin was significantly and inversely correlated with eGFR (r = –0.79, p < 0.0001) and positively correlated with urine albumin (r = 0.71, p < 0.0001) in the study participants. There was a strong dose-response and the significant relationship between serum visfatin level and CKD severity, assessed by GFR and albuminuria, regardless of established risk factors for CKD, including hypertension, diabetes, and cardiovascular disease.
CONCLUSION: Our results show that circulating visfatin is associated with the risk and severity of CKD. These results suggest that longitudinal studies and clinical trials should be conducted to investigate if adipocytokines play a role in the development and progression of CKD independent of body mass index or waist circumference. These important findings may advance our further understanding of CKD risk factors.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Levey AS, Coresh J. Chronic kidney disease. Lancet. 2011;379:165-80.
Lim CC, Teo BW, Ong PG, Cheung CY, Lim SC, Chow KY, et al. Chronic kidney disease, cardiovascular disease and mortality: A prospective cohort study in a multi-ethnic Asian population. Eur J Prev Cardiol. 2014;22(8):1018-26. https://doi.org/10.1177/2047487314536873 PMid:24857889
Rüster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transplant. 2013;28(4):iv8-14. https://doi.org/10.1093/ndt/gft191 PMid:24179016
Izadi V, Azadbakht L. Specific dietary patterns and concentrations of adiponectin. J Res Med Sci. 2015;20(2):178-84. PMid:25983773
Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7):461-70. PMid:26022934
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748-58. https://doi.org/10.4049/ jimmunol.178.3.1748 PMid:17237424
Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant. 2010;25(3):901-6. https://doi.org/10.1093/ndt/gfp587 PMid:19948877
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European society of cardiology (ESC) and the European society of hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. https://doi.org/10.1201/b17072-61
Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55(4):515-24. https://doi.org/10.1016/j.metabol.2005.11.004 PMid:16546483
Levey AS, Cores J, Greene T, Lesley AS, Zhang Y, Hendrickson S, et al, The Chronic Kidney Epidemiology Collaboration. Using standardized serum keratinize values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-54. https://doi.org/10.7326/0003-4819-145-4-200608150-00004 PMid:16908915
Kang YS, Song HK, Lee MH, Ko GJ, Han JY, Han SY, et al. Visfatin is upregulated in Type-2 diabetic rats and targets renal cells. Kidney Int. 2010;78(2):170-81. https://doi.org/10.1038/ ki.2010.98 PMid:20375985
Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. Visfatin: A new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol. 2008;295(5):F1485- 94. https://doi.org/10.1152/ajprenal.90231.2008 PMid:18768589
Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2008;23(3):959-65. https://doi.org/10.1093/ndt/gfm727 PMid:17984105
Mu J, Feng B, Ye Z, Yuan F, Zeng W, Luo Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol. 2011;24(2):177-84. https://doi.org/10.5301/jn.2010.3488 PMid:20602330
Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49(2):237-44. https://doi.org/10.1053/j.ajkd.2006.11.021
Mahmood N, Junejo AM, Jamal Q, Awan R. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes. J Pak Med Assoc. 2010;60(11):922-6. PMid:21375196
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Oleksii Korzh, Anna Titkova, Yana Fylenko (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
